PMID- 32135124
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20211204
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 876
DP  - 2020 Jun 5
TI  - Allicin alleviates inflammation of diabetic macroangiopathy via the Nrf2 and 
      NF-kB pathway.
PG  - 173052
LID - S0014-2999(20)30144-8 [pii]
LID - 10.1016/j.ejphar.2020.173052 [doi]
AB  - As diabetic macroangiopathy is becoming increasingly prevalent, it is urgent to 
      explore preventive and therapeutic drugs and study the mechanism. Diabetic mice 
      were induced by intraperitoneal injection of streptozotocin (STZ)for five 
      consecutive days. Diabetic mice were divided into diabetic and allicin groups. 
      After sacrifice, frozen aortic root sections were immunohistochemically stained 
      for nuclear factor erythroid 2-related factor 2 (Nrf2) and inflammation 
      cytokine-tumor necrosis factor alpha (TNF-alpha), and the remaining aortic tissues were 
      analyzed by Western blot for the expression of proinflammation genes. In vitro, 
      Nrf2 and inflammatory relative protein expression levels in Human Umbilical Vein 
      Endothelial Cells (HUVECs) were examined. HUVECs proliferation and apoptosis were 
      measured. TNF-alpha expression was increased in diabetic group compared to that in 
      control group; this effect was alleviated in allicin-treated mice. Inflammation 
      relative protein expression of Vascular Cell Adhesion Molecule 1(VCAM-1), Matrix 
      metalloproteinase 2 (MMP-2), Inducible Nitric Oxide Synthase (iNOS), and monocyte 
      chemotactic protein 1 (MCP-1) was higher in the diabetic group than in the 
      control group; however, allicin treatment inhibited these diabetes-induced 
      increase. In vitro, allicin treatment reversed the hyperglycemia-induced 
      reduction in proliferation, and decreased the apoptosis induced by high glucose. 
      Inflammation relative protein expression was consistent with that in vivo. 
      Additionally, the expression of nuclear factor kappa-B (NF-kappaB)and Nrf2 was 
      increased in both DM mice and HUVECs; allicin treatment induced a significant 
      reduction in NF-kappaB level and improvement in Nrf2 level. Allicin alleviates 
      inflammation caused by diabetic macroangiopathy, and the mechanism may occur via 
      increasing Nrf2 and decreasing NF-kappaB.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Li, Chang-Ling
AU  - Li CL
AD  - Department of Traditional Chinese Medicine, Qilu Hospital of Shandong University, 
      Jinan, Shandong, 250012, PR China.
FAU - Liu, Xiao-Hong
AU  - Liu XH
AD  - Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250355, PR 
      China.
FAU - Qiao, Yun
AU  - Qiao Y
AD  - Department of Traditional Chinese Medicine, Qilu Hospital of Shandong University, 
      Jinan, Shandong, 250012, PR China.
FAU - Ning, Lu-Ning
AU  - Ning LN
AD  - Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250355, PR 
      China.
FAU - Li, Wen-Jing
AU  - Li WJ
AD  - Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250355, PR 
      China.
FAU - Sun, Ying-Shan
AU  - Sun YS
AD  - Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250355, PR 
      China.
FAU - Liu, De-Shan
AU  - Liu DS
AD  - Department of Traditional Chinese Medicine, Qilu Hospital of Shandong University, 
      Jinan, Shandong, 250012, PR China. Electronic address: liudeshan@sdu.edu.cn.
FAU - Gao, Wei
AU  - Gao W
AD  - Department of Traditional Chinese Medicine, Qilu Hospital of Shandong University, 
      Jinan, Shandong, 250012, PR China.
FAU - Ma, Chun-Mei
AU  - Ma CM
AD  - Department of Traditional Chinese Medicine, Qilu Hospital of Shandong University, 
      Jinan, Shandong, 250012, PR China.
LA  - eng
PT  - Journal Article
DEP - 20200302
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Blood Glucose)
RN  - 0 (Disulfides)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NF-kappa B)
RN  - 0 (Sulfinic Acids)
RN  - 3C39BY17Y6 (allicin)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Blood Glucose/analysis
MH  - Cell Proliferation/drug effects
MH  - Diabetes Mellitus, Experimental/*drug therapy/immunology/metabolism
MH  - Diabetic Angiopathies/immunology/metabolism/pathology/*prevention & control
MH  - Disulfides
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Inflammation
MH  - Male
MH  - Mice, Inbred C57BL
MH  - NF-E2-Related Factor 2/*metabolism
MH  - NF-kappa B/*metabolism
MH  - Streptozocin
MH  - Sulfinic Acids/administration & dosage/*pharmacology
OTO - NOTNLM
OT  - Allicin
OT  - Diabetic macroangiopathy
OT  - Inflammation
OT  - NF-kappaB
OT  - Nrf2
COIS- Declaration of competing interest No conflicts of interest are declared.
EDAT- 2020/03/07 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/03/06 06:00
PHST- 2019/10/30 00:00 [received]
PHST- 2020/02/26 00:00 [revised]
PHST- 2020/02/28 00:00 [accepted]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
PHST- 2020/03/06 06:00 [entrez]
AID - S0014-2999(20)30144-8 [pii]
AID - 10.1016/j.ejphar.2020.173052 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2020 Jun 5;876:173052. doi: 10.1016/j.ejphar.2020.173052. Epub 
      2020 Mar 2.